Inmed Pharmaceuticals Inc (INM)

Jun 11, 2026

InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN

Jun 11, 2026

Jun 10, 2026

Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan

Jun 10, 2026

Jun 10, 2026

Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView

Jun 10, 2026

Jun 10, 2026

InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - TipRanks

Jun 10, 2026

Jun 10, 2026

InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView

Jun 10, 2026

Jun 10, 2026

Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan

Jun 10, 2026

Jun 09, 2026

Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN

Jun 09, 2026

Jun 09, 2026

InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com

Jun 09, 2026

Jun 08, 2026

InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo

Jun 08, 2026

Jun 05, 2026

InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com

Jun 05, 2026

Jun 05, 2026

ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan

Jun 05, 2026

Jun 04, 2026

InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK

Jun 04, 2026

Jun 04, 2026

InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia

Jun 04, 2026

Jun 04, 2026

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile

Jun 04, 2026

Jun 03, 2026

Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus

Jun 03, 2026

Jun 02, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 02, 2026

May 28, 2026

InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks

May 28, 2026

May 27, 2026

Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan

May 27, 2026

May 27, 2026

InMed Pharmaceuticals (INM) Shares Slide Over 3% as Biotech Volatility IntensifiesInstitutional Flow Picks - newsline.com

May 27, 2026

May 26, 2026

InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate

May 26, 2026

May 24, 2026

INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative

May 24, 2026

May 23, 2026

InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser

May 23, 2026

May 23, 2026

InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser

May 23, 2026

May 22, 2026

InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate

May 22, 2026

May 22, 2026

InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co

May 22, 2026

May 21, 2026

ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan

May 21, 2026

May 21, 2026

InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan

May 21, 2026

May 20, 2026

InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co

May 20, 2026

May 20, 2026

INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com

May 20, 2026

May 20, 2026

/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire

May 20, 2026

May 20, 2026

Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0

May 20, 2026

May 20, 2026

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²

May 20, 2026

May 20, 2026

Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter

May 20, 2026

May 20, 2026

InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart

May 20, 2026

May 20, 2026

InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus

May 20, 2026

May 19, 2026

Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang

May 19, 2026

May 19, 2026

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire

May 19, 2026

May 19, 2026

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.

May 19, 2026

May 19, 2026

Mentari, InMed Merge In Deal Backed By $290M Funding - Law360

May 19, 2026

May 19, 2026

InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io

May 19, 2026

May 19, 2026

InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart

May 19, 2026

May 19, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

May 19, 2026

May 19, 2026

InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK

May 19, 2026

May 19, 2026

InMed Soars 100% on $290M Migraine Deal - TechStock²

May 19, 2026

May 19, 2026

InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus

May 19, 2026

May 19, 2026

Trending Stocks Today | Amesite Surges 150.6% - Moomoo

May 19, 2026